Drugs / MGD007
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02248805 | Oct 2014 → Jul 2018 | colorectal carcinoma | MacroGenics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03531632 | Jun 2018 → Feb 2020 | colorectal cancer | MacroGenics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MGD007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02248805 ↗ |
| Modality | Protein / enzyme biologic | “MGD007, a Humanized gpA33 × CD3 DART® Protein” NCT03531632 ↗ |
| Route | Intravenous | “MGD007 and MGA012 are administered by IV infusion.” NCT03531632 ↗ |